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Pathophysiology and Treatment of Life-Threatening Angioedema
Stephen J. Hoffman RN, BSN, CCRN
Otterbein University, Westerville, Ohio
Introduction
Angioedema is a potentially lethal swelling of the
interstitial space from extravasation of intravascular
plasma (Wood, Choromanski, & Orlewicz, 2013).
Angioedema may present in any medical setting with a
broad range of severity. Angioedema is commonly seen
in emergency departments and intensive care units.
According to Barbara, Ronan, Maddox, & Warner
(2013), “angioedema is of particular importance to
anesthesiologists, as it may present at any point in the
perioperative period and it may rapidly become lifethreatening if it involves airway compromise” (p. 335).
Anesthesia professionals may also respond to airway
management emergencies throughout the hospital
setting and may treat angioedema secondary to
anesthetics. Emergency providers and advanced
practitioners should be able to recognize the signs and
symptoms, differentiate between histaminergic and
non-histaminergic, and provide emergent treatment of
angioedema in all care settings.

Classification
Primary angioedema may be classified as mast cell
mediated (histaminergic) or bradykinin mediated (nonhistaminergic) (Bartal, Zeldetz, Stavi, & Barski, 2015).
Angioedema can be caused by reactions to many
different substances including drugs, food, and insect
bites/stings (Barbara et al., 2012). The most common
drugs associated with angioedema are angiotensin
converting enzyme (ACE) inhibitors, ARBs, antibiotics,
muscle relaxants, opioids, NSAIDS, and raidiocontrast
agents (Barbara et al., 2012). Sonny, Avitsian, Hussain,
& Elsharkawy (2015) note a 1.3% to 5.1% incidence of
angioedema following infusion of recombinant tissue
plasminogen activator (rtPA). Hereditary angioedema
episodes can be triggered by stress trauma, estrogen,
or surgery, especially dental surgery (Senaratne,
Cottrell, & Prentice, 2012). Secondary angioedema may
present as a symptom of anaphylaxis, “a sever life
threatening generalized or systemic hypersensitivity
reaction” (Dhami et al. 2013, p.169).

Characteristics of Edema
•
•
•
•
•

Non-pitting
Non-gravity dependent
Often asymmetric
Transient
Self-Limiting

•
•
•
•
•
•

Face
Eyelids
Tongue
Oral cavity
Neck
Throat

Location
•
•
•
•
•

Glottic
structures
Extremitie
s
Trunk
Genitals
Bowel

Signs and Symptoms
•
•
•
•
•
•
•
•
•
•
•
•

Dyspnea
Dysphagia
Odynophagia
Stridor
Hoarseness
Drooling
Tachypnea
Hypovolemic shock
Hypotension
Tachycardia
Urticaria (histaminergic only)
Abdominal pain (Bowel edema may present
like an acute abdomen; avoid surgery.)

•
•

Vomiting (Hereditary Angioedema; HAE)
Weakness (HAE)

Nursing Implications
•
•
•

•
•
•
•

Assess the extent of tissue
involvement
Apply treatment algorithms
Ongoing assessment of airway,
vital signs, symptom progression,
and response to treatment
Continuous cardiac monitor
Continuous pulse-ox
Fluid resuscitation
Medical & family history

Treatment
It is important to differentiate between histaminergic
angioedema, non-histaminergic angioedema (bradykinin),
and anaphylactic reactions. For all etiologies, treatment can
begin with anti-histamines and corticosteroids, and include
epinephrine in the presence of stridor, new hoarseness of
voice, or life threatening reaction (Moellman, Bernstein, &
Lindsell, 2014). Although Moellman et al. (2014) note that
“the only potential acute treatment currently readily available
for the treatment of ACE-induced or other bradykininmediated angioedema in the ED is fresh-frozen plasma (FFP)”
(p. 473), approved plasma C1-INH protein concentrates,
kallikrein inhibitors (Ecallantide), and bradykinin 2-receptor
blockers (Icatibant) may be available at some facilities when
patients are suspected to have hereditary angioedema and
can be considered for other non-histaminergic (bradykinin
induced) angioedema (Moellman et al. 2014).

Pathophysiology
Histamine vs. Bradykinin
Histaminergic angioedema is an IgE
mediated, type 1 hypersensitivity reaction
that results in the degranulation of histamine
from granulocytes, primarily mast cells.
Histamine release causes localized
vasodilation and increased vascular
permeability resulting in the extravasation of
intravascular plasma into the interstitial
space causing swelling of the subcutaneous
and submucosal tissues (Wood et al., 2013).
Because the majority of angioedema cases
are histaminergic reactions, first line
medications for treatment of all types of
angioedema include anti-histamines (H1 and
H2 receptor blockers), corticosteroids to
blunt the immune response, and epinephrine
to inhibit mast cell degranulation (Moellman,
Bernstein, & Lindsell, 2014).

A

Non-histaminergic angioedema is
bradykinin mediated and can be due
to hereditary deficiency or
dysfunction of C1-inhibitor, or drugs
including ACE inhibitors. Bradykinin
is an inflammatory mediator that
causes vasodilation, increased
vascular permeability, nonvascular
smooth muscle contraction, and
oedema formation (Spyridonidou et
al., 2010). It should be noted that
anti-histamines and corticosteroids
are ineffective in the treatment of
non-histaminergic angioedema, and
epinephrine is only minimally
effective (Moellman, et al. 2014).

B

Significance of Pathophysiology
Hereditary angioedema (HAE) is caused by an autosomal dominant defect in the C1INH gene that results in low levels of C1 esterase inhibitor (C1-INH) or ineffective C1-INH
protein (Senaratne et al. 2012). C1-INH is a protein responsible for the inhibition of the
complement inflammatory pathway and inhibition of B2 receptors in the kinin pathway
(Senaratne et al. 2012). Without inhibition of the kinin pathway, bradykinin levels rise
resulting in episodic angioedema. Rarely C1-INH may become deficient due to the
development of autoantibodies or a lymphoproliferative disorder (Moellman et al., 2014).
Diagnosis of HAE is difficult in the acute setting, but HAE can be suspected if the
patient’s family history indicates autosomal dominant penetrance. Moellman et al. (2014)
recommends checking serum C4 and tryptase levels during acute episodes of suspected HAE
to aid in diagnosis, but these values are rarely useful in the acute setting and provide the
most utility to immunologists in follow-up appointments. Serum C1 inhibitor level and C1
inhibitor activity level may be used in sub-acute setting (Senaratne et al. 2012). Plasma C1INH concentrates, B2 receptor antagonists (icatibant), and kallikrein receptor blockers
(ecallantide) can be used to treat bradykinin-mediated angioedema in the acute setting
(Moellman et al., 2014) or prophylactically in the preoperative and perioperative setting
(Senaratne et al., 2012).
ACE inhibitor therapy can cause angioedema at any time, but most reactions occur
within the first few weeks after initiation or dose changes (Chan & Soliman, 2015).
Angiotensin converting enzyme (ACE, identical to Kinase II) is responsible for the
breakdown of bradykinin at the B2 receptor on the cell membrane (Bartal et al. 2015). When
ACE (Kinase II) is inhibited, bradykinin levels can progressively increase and cause
angioedema. Discontinue the ACE inhibitor. Fresh frozen plasma administration has been
successfully used to treat ACE inhibitor related angioedema presumably because plasma
contains small amounts of Kinase II (ACE), which can breakdown excess bradykinin
(Senaratne et al. 2012). More research needs to be completed on the potential benefit of
administering plasma C1-INH concentrate, B2 receptor antagonist, or kallikrein receptor
blockers in patients with ACE inhibitor induced angioedema. (off-label use) (Moellman et al.,
2014) . However, small studies are emerging with promising results. Bartal, Zeldetz, Stavi, &
Barski (2015) presented a case study that showed rapid resolution of ACE inhibitor induced,
refractory, life-threatening laryngeal edema after a single subcutaneous icatibant (B2
antagonist) injection. Other case studies show similar results (Bartal et al. 2015).

Airway Risk Assessment Tools

The tongue swelling of a patient with ACE inhibitor induced angioedema, before (A) and
30 minutes after (B) treatment with 30mg SubQ icatibant, Source: Bartal, Zeldetz, Stavi, &
Barski, p. 479e2 (2015).

Estimated Classification in Primary Angioedema
Cases Presenting to the Hospital

62%
Histamine

34%

1%

ACE inhibitor
(Bradykinin)

C1EI
(Bradykinin)

In 2001, Chiu, Newkirk, Davidson,
Burningham, Krowiak, & Deeb (2001)
classified patients with angioedema into 3
risk categories for intubation based on the
specific locations of facial, oral, and
oropharyngeal swelling. Type 1 included
facial and oral edema that excluded the floor
of the mouth (0% intubated); type 2
included oropharynx and/or floor of the
mouth edema (21.4% intubated, 7.1%
surgical airway), and type 3 included
oropharyngeal edema including the
supraglottic and glottic structures (33.3%
intubated) (Chiu et al, 2001). This
categorization system for patients with
angioedema remains useful for airway risk
assessment when airways are not acutely
compromised and fiberoptic bronchoscopy is
immediately available (Wood et al., 2013).

In 1999, Ishoo, Shah, Grillone, Stram, and
Fuleihan proposed a staging criteria for
angioedema: stage 1 facial rash, facial edema,
and lip edema, stage 2 soft palate edema,
stage 3 lingual edema, and stage 4 laryngeal
edema. Stages 1 and 2 could be treated
outpatient or as inpatient observational, while
7% of stage 3 and 24% of stage 4 required
artificial airways (Ishoo et al. 1999). Ishoo et
al. (1999) found that voice changes,
hoarseness, dyspnea, and stridor were the
strongest predictors of the need for an
artificial airway. Moellman et al. (2014) note
that while the Ishoo criteria have been used
for years to help decide whether to admit or
discharge a patient, “these criteria have not
yet been validated” (p. 473). While more
information may be needed, the Ishoo criteria
and study remain useful.

Conclusion
Healthcare providers need to be able to promptly recognize the clinical manifestations of
angioedema because airway involvement and hypovolemic shock can be life-threatening. Airway
management is of primary importance. Most angioedema reactions are histaminergic. Bradykininmediated angioedema is becoming more common with increased use of ACE inhibitors. Hereditary
angioedema should be recognized with a detailed family history, and prophylactic treatment prior to
surgical procedures is recommended (Moellman et al. 2014). Patients presenting with angioedema
rely on healthcare providers to possess the clinical skill and medical expertise to prevent adverse
outcomes.
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